Design and nonviral delivery of live attenuated vaccine to prevent chronic hepatitis C virus-like infection

Sheetal Trivedi, Piyush Dravid, Tim C. Passchier, Satyapramod Murthy, Kripa Shanker Kasudhan, Narendran Reguraman, Justin Kellar, Rahul Chandra, Cole Cassady, Peter D. Burbelo, Arash Grakoui, Himanshu Sharma, Peter Simmonds and Amit Kapoor ()
Additional contact information
Sheetal Trivedi: The Research Institute at Nationwide Children’s Hospital
Piyush Dravid: The Research Institute at Nationwide Children’s Hospital
Tim C. Passchier: University of Oxford
Satyapramod Murthy: The Research Institute at Nationwide Children’s Hospital
Kripa Shanker Kasudhan: The Research Institute at Nationwide Children’s Hospital
Narendran Reguraman: The Research Institute at Nationwide Children’s Hospital
Justin Kellar: The Research Institute at Nationwide Children’s Hospital
Rahul Chandra: The Research Institute at Nationwide Children’s Hospital
Cole Cassady: The Research Institute at Nationwide Children’s Hospital
Peter D. Burbelo: National Institutes of Health
Arash Grakoui: Emory University
Himanshu Sharma: The Research Institute at Nationwide Children’s Hospital
Peter Simmonds: University of Oxford
Amit Kapoor: The Research Institute at Nationwide Children’s Hospital

Nature Communications, 2025, vol. 16, issue 1, 1-13

Abstract: Abstract An effective vaccine for the hepatitis C virus (HCV) remains an unmet medical need. There is no animal model for assessing HCV vaccines; however, rodent hepacivirus (RHV) infection in laboratory rats recapitulates the lifelong chronic hepatotropic infection and immune evasion of HCV. Here, we designed a live-attenuated vaccine (LAV) for RHV and determined its immunogenicity and efficacy for preventing chronic infection. The LAV strains are generated by synonymous mutagenesis to increase the frequencies of naturally suppressed dinucleotides, UpA or CpG, in genomic regions that lack extensive RNA secondary structures. Rats vaccinated using LAV containing infectious virions (LAV-IV), or lipid nanoparticle-encapsulated viral RNA (LNP-vRNA) developed short-term viremia and robust T cell responses. After challenge with RHV-rn1, while all unvaccinated rats developed chronic infection, 75% and 85% of rats vaccinated with LAV-IV and LAV-vRNA cleared the infection. Clearance of RHV-rn1 was associated with expansion of memory T cells, transient rise in serum ALT, and, more importantly, enhanced protection against reinfection. In conclusion, we identified a genomic region of hepacivirus that can be synonymously mutated to attenuate its persistence, and vaccines based on these modified genomes protect against chronic hepacivirus infection, a strategy with an apparent translational path toward HCV immunization.

Date: 2025
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-025-62813-8 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-62813-8

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-025-62813-8

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().